AffyImmune Therapeutics

Affy Immune Therapeutics

Biotechnology, 22 Strathmore Rd, Natick, Massachusetts, 01760, United States, 11-50 Employees

affyimmune.com

  • twitter
  • LinkedIn

phone no Phone Number: 15*********

Who is AFFYIMMUNE THERAPEUTICS

Founded in 2016, AffyImmune is a clinical-stage biotechnology company that optimizes CAR T cells for the treatment of solid tumors using our Tune & Track platform. AIC100, our first produ...

Read More

map
  • 22 Strathmore Rd, Natick, Massachusetts, 01760, United States Headquarters: 22 Strathmore Rd, Natick, Massachusetts, 01760, United States
  • 2016 Date Founded: 2016
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8731

checked-icon Does something look wrong? Fix it. | View contact records from AFFYIMMUNE THERAPEUTICS

AffyImmune Therapeutics Org Chart and Mapping

Employees

Eric Dunn

Cmc Logistics Manager

Karrie Du

Senior Cmc Associate

Aishwarya Raghuraman

Cmc Associate, Analytical Development

Srinija Alla

Senior Research Associate- R&D Project Management

Dawn Buchanan

Vice President Clinical Operations

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding AffyImmune Therapeutics

Answer: AffyImmune Therapeutics's headquarters are located at 22 Strathmore Rd, Natick, Massachusetts, 01760, United States

Answer: AffyImmune Therapeutics's phone number is 15*********

Answer: AffyImmune Therapeutics's official website is https://affyimmune.com

Answer: AffyImmune Therapeutics's revenue is $1 Million to $5 Million

Answer: AffyImmune Therapeutics's SIC: 8731

Answer: AffyImmune Therapeutics has 11-50 employees

Answer: AffyImmune Therapeutics is in Biotechnology

Answer: AffyImmune Therapeutics contact info: Phone number: 15********* Website: https://affyimmune.com

Answer: Founded in 2016, AffyImmune is a clinical-stage biotechnology company that optimizes CAR T cells for the treatment of solid tumors using our Tune & Track platform. AIC100, our first product, spares healthy cells through our unique affinity-tuning, enhancing its safety and efficacy. The initial indication for AIC100 is refractory thyroid cancer, which has a very poor prognosis and very few effective therapies. The antigen targeted by AIC100 is also overexpressed in a variety of additional cancers, including stomach, triple negative breast cancer and a number of others.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access